Literature DB >> 421728

Systemic availability of ergotamine tartrate after oral, rectal and intramuscular administration.

V Ala-Hurula, V V Myllylä, P Arvela, J Heikkilä, N Kärki, E Hokkanen.   

Abstract

Plasma ergotamine levels were measured in 33 volunteers (subgroups 11, 12 and 10) after a single dose of ergotamine administered by various routes. Ergotamine tartrate was given in doses normally used in the treatment of acute migraine--2.0 mg orally, 2.0 mg combined with 100 mg caffeine rectally and 0.5 mg i.m. Plasma ergotamine concentrations were determined by radioimmunoassay. The highest and longest lasting levels were found after i.m. administration, the peak concentration being 1.94 +/- 0.34 (SEM) ng/ml at 1/2 h. The corresponding maximum concentrations after oral and rectal administration were 0.36 +/- 0.08 ng/ml at 2 h and 0.42 +/- 0.09 ng/ml at 1 h. In most of the subjects the plasma ergotamine level began to rise again at 24 to 48 h. The cause of the elevation is not known but it might favour possible accumulation of the drug. Absorption from suppositories was at least as good as after oral administration and the former route may therefore be advantageous for migraine patients in whom nausea and vomiting during an attack may prevent efficient oral medication.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 421728     DOI: 10.1007/bf00563557

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  6 in total

1.  Historical development of the ergot therapy of migraine.

Authors:  E ROTHLIN
Journal:  Int Arch Allergy Appl Immunol       Date:  1955

2.  Responsiveness of isolated canine cerebral and peripheral arteries to ergotamine.

Authors:  E Müller-Schweinitzer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1976       Impact factor: 3.000

3.  Selective carotid vasoconstriction by ergotamine as a relevant mechanism in its antimigraine action.

Authors:  P R Saxena
Journal:  Arch Neurobiol (Madr)       Date:  1974

4.  9-10-dihydroergotamine: production of antibodies and radioimmunoassay.

Authors:  J Rosenthaler; H Munzer
Journal:  Experientia       Date:  1976-02-15

5.  Quantitative thin-layer chromatographic analysis of ergotamine tartrate and caffeine in the nanogram range.

Authors:  M Amin; W Sepp
Journal:  J Chromatogr       Date:  1976-03-17

6.  Comparative pharmacokinetic investigations with tritium-labeled ergot alkaloids after oral and intravenous administration man.

Authors:  W H Aellig; E Nüesch
Journal:  Int J Clin Pharmacol Biopharm       Date:  1977-03
  6 in total
  12 in total

1.  Systemic availability of ergotamine tartrate after three successive doses and during continuous medication.

Authors:  V Ala-Hurula; V V Myllylä; P Arvela; N T Kärki; E Hokkanen
Journal:  Eur J Clin Pharmacol       Date:  1979-11       Impact factor: 2.953

2.  Correlation between pharmacokinetics and clinical effects of ergotamine in patients suffering from migraine.

Authors:  V Ala-Hurula
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

3.  Lithium in migraine and cluster headache: a review.

Authors:  R C Peatfield
Journal:  J R Soc Med       Date:  1981-06       Impact factor: 5.344

Review 4.  Clinical pharmacokinetics of ergotamine in migraine and cluster headache.

Authors:  V L Perrin
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

Review 5.  Rectal drug administration: clinical pharmacokinetic considerations.

Authors:  A G de Boer; F Moolenaar; L G de Leede; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1982 Jul-Aug       Impact factor: 6.447

6.  Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers.

Authors:  J J Ibraheem; L Paalzow; P Tfelt-Hansen
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

7.  Ergotamine absorption and toxicity.

Authors:  D A Orton; R J Richardson
Journal:  Postgrad Med J       Date:  1982-01       Impact factor: 2.401

Review 8.  First-pass elimination. Basic concepts and clinical consequences.

Authors:  S M Pond; T N Tozer
Journal:  Clin Pharmacokinet       Date:  1984 Jan-Feb       Impact factor: 6.447

9.  Kinetics of ergotamine after intravenous and intramuscular administration to migraine sufferers.

Authors:  J J Ibraheem; L Paalzow; P Tfelt-Hansen
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

10.  Ergotism in a patient with a portosystemic shunt.

Authors:  V Hansteen; C Eika; S Birkeland
Journal:  Eur J Clin Pharmacol       Date:  1979       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.